missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human NETO1 (aa 112-162) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (100%), Rat (100%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-66699 (PA5-66699. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
This gene encodes a predicted transmembrane protein containing two extracellular CUB domains followed by a low-density lipoprotein class A (LDLa) domain. A similar gene in mice encodes a protein that plays a critical role in spatial learning and memory by regulating the function of synaptic N-methyl-D-aspartic acid receptor complexes in the hippocampus. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene.
Specifications
Specifications
| Accession Number | Q8TDF5 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 81832 |
| Name | Human NETO1 (aa 112-162) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | AI851453; BCTL1; brain-specific transmembrane protein containing 2 CUB and 1 LDL-receptor class A domains protein 1; Btcl1; C130005O10Rik; NETO1; neuopilin- and tolloid-like 1; neuropilin (NRP) and tolloid (TLL)-like 1; neuropilin and tolloid like 1; neuropilin- and tolloid-like protein 1; neuropilin and tolloid-like protein 1; RGD1566269; si:dkey-82k12.12 |
| Common Name | NETO1 |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction